A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Among the leading biotech organisations, innovators and solution providers joining the show, are Discovery Park, Thistle ...

Illumina & NashBio announce Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery: San Diego Friday, March 21, 2025, 10:00 Hrs [IST] Illumina ...

Among the leading biotech organisations, innovators and solution providers joining the show, are Discovery Park, Thistle ...

Recursion Pharmaceuticals appointed former FDA principal deputy commissioner Namandjé Bumpus, PhD, and Elaine Sun, the COO and CFO of Mammoth Biosciences, to its board of directors. CAMP4 Therapeutics ...

U.S. Contraceptives Drugs And Devices Market Demand BURLINGAME, CA, UNITED STATES, March 18, 2025 /EINPresswire / -- The Global U.S. Contracep ...

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

L.L. has acted as a consultant for Merck, Novartis, and Bayer, and has received grants from Pfizer, Bayer, Merck, and Novartis. D.C.B. has served on the steering committee as a consultant for Merck.

Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.